GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Terumo Corp (TSE:4543) » Definitions » Institutional Ownership

Terumo (TSE:4543) Institutional Ownership : 47.24% (As of Apr. 30, 2025)


View and export this data going back to 1982. Start your Free Trial

What is Terumo Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Terumo's institutional ownership is 47.24%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Terumo's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Terumo's Float Percentage Of Total Shares Outstanding is 0.00%.


Terumo Institutional Ownership Historical Data

The historical data trend for Terumo's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Terumo Institutional Ownership Chart

Terumo Historical Data

The historical data trend for Terumo can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 44.88 44.85 45.08 45.81 47.15 47.38 47.72 47.63 47.45 47.24

Terumo Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Terumo Business Description

Traded in Other Exchanges
Address
2-44-1 Hatagaya, Shibuya-ku, Tokyo, JPN, 151-0072
Started as a clinical thermometer producer in Japan in 1921, Terumo is a comprehensive medical device player with a diversified global revenue. Its product portfolio includes prefilled syringes, insulin patch pumps, neurovascular or cardiac vascular interventional devices, and blood processing systems. As of 2024, the cardiac and vascular business is the largest segment, contributing over 60% of its total revenue. Geographically, North America is the largest region, with 36% of Terumo's revenue.

Terumo Headlines

No Headlines